An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: An analysis of the RENAAL study adapted to France

Diabetes and Metabolism

Volumn 29, Issue 1, 2003, Pages 29-35

  Souchet, T ^a   Zaleski, I Durand ^b   Hannedouche, T ^c   Rodier, M ^d   Gaugris, S ^a   Passa, P ^e  

^a Dohme Chibret Centre de Recherche Riom   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL CIVIL   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

Cost; Diabetic Nephropathy; End Stage Renal Disease; Losartan; Type 2 Diabetes

Indexed keywords

LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; FRANCE; HEALTH CARE UTILIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA;

EID: 0345700288     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70004-6     Document Type: Article

References (20)

1. Halimi S, Zmirou D, Benhamou PY, et al. Huge progression of diabetes prevalence and incidence among dialysed patients in mainland France and overseas French territories. A second national survey six years apart. (UREMIDIAB 2 Study) Diabetes Metab, 1999, 25, 50712.
2. Pouteil-Noble C. Epidémiologie et étiologie de l'insuffisance rénale chronique. La Revue du Praticien, 2001, 51, 365-71.
3. Ricordeau P, Weill A, Vallier N, Bourrel R, Allemand H. L'épidémiologie du diabète de type 2 en France métropolitaine. Diabetes Metab, 2000, 26, 11-24.
4. National Institutes of Health. Excerpts from the United States Renal Data System's 2000 annual report; atlas of end-stage renal disease in the United States: incidence and prevalence of ESRD. Am J Kidney Dis, 2000, 36, S37-S54.
5. Jacobs C. The costs of dialysis treatments for patients with end-stage renal disease in France. Nephrol Dial Transplant. 1997, 12, 29-32.
6. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001, 345, 861-9.
7. Carides GW, Heyse JF, Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics, 2000, 1, 299-313.
8. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman Hall, 1993.
9. Ricordeau P, Weill A, Vallier N, et al. Le coût du diabète en France métropolitaine. Diabetes Metab, 2000, 26, 25-38.
10. Walker WG, Herman J, Anderson J, Zachary J, Russell RP. Blood pressure (BP) control slows decline of glomerular filtration rate (GFR) in hypertensive NIDDM patients. J Am Soc Nephrol, 1992, 3, abstract.
11. Lebovitz HE, Wiegmann TB, Cnaam A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int, 1994, 45, S150-S155.
12. Bakris GL, Coplet JB, Vicknair N, Sadler R, Leurgans, S. Calcium channel blockers versus other antihypertensives therapies on progression of NIDDM associated nephropathy. Kidney Int, 1996, 50, 1641-50.
13. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes, 1997, 46, 1182-8.
14. Fogari R, Zoppi A, Corradi L, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertension, 1999, 13, 47-53.
15. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care, 2000, 23, B54-B64.
16. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus/results of HOPE and MICRO-HOPE substudy. Lancet, 2000, 355, 253-9.
17. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001, 345, 851-60.
18. Tengs TO, Adams ME, Pliskin JS. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis, 1995, 15, 369-90.
19. Lewis E. The effect of angiotensin-converting inhibition on diabetic nephropathy. N Engl J Med, 1993, 329, 1456-62.
20. Le Pen C, Petitjean Ph, Lévy P, Hannedouche T. L'évaluation économique de l'apport du captopril dans le traitement de la néphropathie diabétique: une approche coût-efficacité. Néphrologie, 1996, 17, 321-6.